Man Group’s Tonix Pharmaceuticals TNXP Stock Holding History

Man Group’s Portfolio TNXP Stock Details TNXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-18,442	Closed	-$288K	–	2581
2025 Q4	$288K	Buy	+18,442	New	+$340K	﹤0.01%	2030
2022 Q4	–	Sell	-1	Closed	-$14K	–	2223
2022 Q3	$14K	Buy	+1	New	+$24.5K	﹤0.01%	1954
2022 Q2	–	Hold	0	–	–	–	1988

Other funds holding TNXP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JHC

Jones Hill Capital New York $466M AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Man Group's TNXP Position: Q1 2026 in Review

Man Group sold out of Tonix Pharmaceuticals (TNXP) in Q1 2026, closing a stake of 18,442 shares — an estimated $288K sold.

Man Group first reported a position in TNXP in Q3 2022 and held it in 2 quarters. The position peaked at $288K in Q4 2025. 81 funds tracked by Wall St. Rank hold TNXP as of Q1 2026.

Man Group reported no remaining Tonix Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Man Group sold 18,442 Tonix Pharmaceuticals shares in Q1 2026, an estimated $288K.
Man Group first reported a position in Tonix Pharmaceuticals in Q3 2022 and held it in 2 quarters.
Man Group's Tonix Pharmaceuticals position peaked at $288K in Q4 2025.
81 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q1 2026.

Based on Man Group's 13F filing for Q1 2026, filed 15 May 2026.